Mizuho maintains Neutral rating on Apellis stock with steady price target - Investing.com

Mizuho maintains Neutral rating on Apellis Pharmaceuticals with $42.00 price target, as EMA's CHMP to review pegcetacoplan approval. Despite 39% stock decline YTD, caution advised due to 10% approval probability. Apellis's Phase 3 VALIANT trial success and Q2 2024 revenue growth highlight potential, though profitability remains uncertain.